On the Operational Update Investor Call dated February 13, 2018, Dr. Robert Hayes mentioned that the challenge with regards to CRISPR / CAS9 has always been getting these large enzymes into cells and how inefficient the current delivery system is with regards to CRISPR / CAS9, with delivery and efficiency only at around 1% in many cells.
This recent in vitro CRE experiment has shown that not only successful delivery of CRE inside cells, but also being able do it in a cell specific manner. This presents a significant potential opportunity. What significance does this experiments' percentage hold for upcoming work that needs to be conducted in live animal testing and why is this experiments' data important for companies working in CRISPR / CAS9 space? Is one of the main reasons because the company's FPPs (in this in vitro CRE experiment) outperformed current delivery standard TAT, with over 50% more uptake into cells?
Tony
PYC Price at posting:
2.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)